A company developing small molecule therapeutics targeting DNA Damage Response (DDR) in order to treat patients with a broad range of cancers has its first assay development customer.
New research findings suggest that an immunotherapy assay enables determination of PD-L1 status in a high percentage of cancer patients and could guide personalized treatment selection.
Clinical trials often rely on outsourced testing which poses potential logistical and cost challenges, though researchers recently demonstrated the viability of bringing these tests in-house to speed turnaround time – and more quickly match patients to...
Assay.Works and 2bind are partnering to expand the range of discovery services provided for companies in the pharmaceutical and biotech industry, and academic organizations.
BioIVT adds transporter assay products and services to its ADME-Toxicology portfolio with the acquisition of Optivia Biotechnology – a deal which aligns with the company’s efforts to support drug safety and efficacy, says VP.
Irish Luxcel will grant access to its consumable in vitro cell toxicity tests to Shanghai-based CRO HD Biosciences to help reduce the risk of post-market drug withdrawal.
Metrion Biosciences has been awarded a grant to develop CiPA-compliant stem cells and screening technologies by Eurostars, a European Union (EU) programme.
Tepnel Research Products & Services has indicated it will soon
begin offering a number of new molecular services at its new
facility in Livingston, Scotland.
A new report out today has revealed that the uptake of assays for
in-vitro diagnostics is being hindered due to a lack of knowledge
of this technology, in which its high sensitivity, specificity and
fast turn-around times has proved...
MiraiBio has released software for the statistical analysis of
multiplexed data generated on its liquid array detection system, a
platform that is designed for immunoassay, enzyme function, and
receptor-ligand interaction applications,...
